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PHARMACOVIGILANCE  
INTRODUCTION 
• The World Health Organization (WHO) defines pharmacovigilance as the science 
and activities relating to the detection, evaluation, understanding, and prevention of 
adverse reactions to medicines or any other medicine-related problems.  
• The definition and scope of pharmacovigilance have evolved to recognize the 
importance of a systems approach for monitoring and improving the safe use of 
medicines.1 
• A simpler definition describes pharmacovigilance as the processes and science of 
monitoring the safety of medicines and taking action to reduce risk and increase 
benefit.2 Therefore, the assessment of benefit versus risk must begin during the 
preclinical evaluation of a medicinal product and must extend throughout its full life 
cycle. 
• As a result, there is now added focus on safety and risk assessment after a product 
has received regulatory approval, when it is placed on the market and prescribed to 
large populations. 
• Although there is no international standard that dictates the components of an 
adequate pharmacovigilance system or the processes to be engaged in risk 
management, there is consensus among the major regulators that 
pharmacovigilance is necessary and important in the development and 
commercialization of medicinal products. 
• Therefore it is essential in building capacity for clinical trials to understand the 
components, the functions, and the processes required for full and effective 
pharmacovigilance and risk management. 
• The amount and variety of safety-relevant data gathered from 
different patient populations in global clinical trials are enormous;  
• therefore it is crucial that a concise and systematic approach to 
pharmacovigilance be implemented. Systematic safety monitoring is 
needed to identify previously recognized and unrecognized adverse 
drug reactions and to evaluate the safety and efficacy of medicinal 
products during clinical trials and in the postmarketing period. 
• It is important that pharmacovigilance not be perceived as a burden 
put upon the pharmaceutical product development industry by the 
regulating bodies. Ongoing pharmacovigilance should be understood 
as essential to the only appropriate way to develop safe medicines, 
introduce them into the market, and have them survive in the market 
once approved.  
• Not only does the failure to perform ongoing safety assessment 
activities increase the chances of placing subjects at risk 
unnecessarily, it also increases a company’s risk of investing in the 
development of the wrong molecules. 
• Capacity building for pharmacovigilance and medicine safety 
should address all processes for developing individual and 
system capacity and enable achievement of sustainable ability 
to manage effectively the safety of patients and health 
products. 
•  Performing systematic pharmacovigilance requires a full 
understanding of the scope of pharmacovigilance, which 
includes both active safety reporting and postmarketing 
surveillance.  
• It involves the ongoing processes of risk identification, risk 
assessment, and risk mitigation.  
• All of these processes are equally important to the 
pharmaceutical company, the regulatory authorities, the 
investigator, and the patient. 
• There are many ways of building pharmacovigilance capability, and 
many differences in how pharmacovigilance systems are created. 
Historically, companies created pharmacovigilance functionality as 
the need arose to assess their products under development. 
•  Since there are variations in the required sample size of studies, 
geographical site distribution, adjuvant or comparator products used, 
and in the definition of “standard treatment” in different countries, 
differences naturally evolved.  
• Global pharmacovigilance is an ongoing process of harmonization. 
• Currently, there are many national, cultural, and regulatory 
differences among countries in how pharmacovigilance is 
implemented.  
• The goal is always the accurate assessment of the benefit versus the 
risk of a product in the populations who receive it, and mature 
pharmacovigilance systems are able reach accurate conclusions 
despite different types of data. 
OPERATIONAL OVERVIEW OF 
PHARMACOVIGILANCE 
• An operational overview of pharmacovigilance begins with 
safety information coming from a variety of sources, including 
clinical trials data, safety call centers, spontaneous reports, and 
literature searches, each of which has the potential to create an 
individual case.  
• Within the pharmacovigilance department each case is 
processed, assessed as to its relationship (causality) to the 
investigational product, and reported to the regulatory 
authorities and other stakeholders, either as an expedited report 
or as part of an aggregate report, based upon 
pharmacovigilance policies, regulations, and guidance 
documents.  
• In addition, each case becomes part of the total safety dataset 
for that medicinal product. 
• Aggregate data are systematically analyzed for safety issues and assessed for benefit 
versus risk, and periodic safety update reports (PSURs) are submitted to the regulatory 
authorities as additional safety information is collected.  
• This continues throughout the product’s life cycle. 
• Safety findings are addressed in order to mitigate risk. This may include modification 
to a clinical trial design, changes in proposed labeling, implementation of a risk 
mitigation plan, or discontinuation of development or use of a marketed product. 
COMPONENTS AND CAPABILITIES OF A 
COMPLETE PHARMACOVIGILANCE 
SYSTEM 
In some companies some activities may be performed by different departments, 
for example, safety regulatory reporting may be part of regulatory affairs, or 
aggregate report writing may be done within a company’s medical writing 
department. Some activities may be outsourced to contract research 
organizations (CROs) or safety niche providers, while others are kept inhouse, 
but all must be covered for complete pharmacovigilance capacity. 
PHARMACOVIGILANCE POLICIES, 
REGULATIONS, AND GUIDANCE 
DOCUMENTS 
• The major regulatory stakeholders driving the formation of 
global pharmacovigilance regulation are the US Food and 
Drug Administration (FDA), the European Medicines Agency 
(EMA), and Japan’s Pharmaceuticals and Medical Devices 
Agency (PMDA).  
• In the USA, the Code of Federal Regulations is legally 
binding, as are the European national laws and ordinances. 
• Directives reflect current thinking on a topic and bind member 
states to common objectives, which must be implemented into 
national law within a given timeframe.  
• Guidance documents, guidelines, and recommendations are not 
legally binding, but should be respected and play an important 
role in actual practice. 
Adverse Event Reporting 
• DEFINITIONS 
• Reporting of adverse events is the cornerstone of pharmacovigilance, 
and therefore closely supervised by regulatory authorities. ICH E2A 
defines the following adverse events (AEs), adverse drug reactions 
(ADRs), and serious adverse events (SAEs) as follows: 
• Adverse event (or adverse experience) 
• Any untoward medical occurrence in a patient or clinical 
investigative subject administered a pharmaceutical product and 
which does not necessarily have to have a causal relationship with 
this treatment. 
• An adverse event (AE) can therefore be an unfavorable and 
unintended sign (including an abnormal laboratory finding, for 
example), symptom or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal 
product. 
Adverse Event Reporting 
• DEFINITIONS 
• Adverse drug reaction 
• In the pre-approval clinical experience with a new medicinal product 
or its new usages, particularly as the therapeutic dose(s) may not be 
established: all noxious and unintended responses to a medicinal 
product related to any dose should be considered adverse drug 
reactions. 
• The phrase “responses to a medicinal product” means that a causal 
relationship between a medicinal product and an adverse event is at 
least a reasonable possibility, i.e. the relationship cannot be ruled out. 
Adverse Event Reporting 
• A serious adverse event (experience) or reaction is any untoward 
medical occurrence at any dose which: 
• results in death, 
• is life threatening, 
• requires inpatient hospitalization or prolongation of existing 
hospitalization, 
• results in persistent or significant disability/incapacity or 
•  is a congenital anomaly/birth defect. 
Medical and scientific judgment should be exercised in deciding 
whether expedited reporting is appropriate in other situations, such as 
important medical events that may not be immediately life-threatening 
or result in death or hospitalization but may jeopardize the patient or 
may require intervention to prevent one of the other outcomes listed in 
the definitionabove. These should also usually be considered serious 
ADVERSE EVENT REPORTING 
TIMELINES 
• According to ICH E6, all SAEs should be reported to the sponsor 
immediately, except for those identified in the protocol or other 
document as not needing immediate reporting. 
• Fatal or unexpected ADRs occurring in clinical investigations should 
be reported to the regulatory authorities as soon as possible, but no 
later than seven calendar days after knowledge of the event by the 
sponsor, followed by as complete a report as possible within eight 
additional calendar days. 
• Serious unexpected reactions (ADRs) which are not fatal or life 
threatening must be filed as soon as possible but no later than 15 
calendar days after first knowledge by the sponsor that the case meets 
the minimum criteria for expedited reporting. 
• Adverse events that do not meet the requirements for expedited 
reporting are reported at the end of the clinical trial as part of the 
marketing application 
ORGANIZATIONAL STRUCTURE OF A 
PHARMACOVIGILANCE DEPARTMENT 
• Departmental Organization 
• The basic functional “unit” within the pharmacovigilance 
department is comprised of the drug safety physician (DSP), 
drug safety associate (DSA), and medical assistant.  
• A “team” may consist of several DSAs, a single physician 
providing medical review, and one or two medical assistants 
for administrative support.  
• Depending on the size of the company and the number of 
employees, pharmacovigilance teams may be organized by 
product or by therapeutic area, or may be separated into 
premarketing and postmarketing groups.  
• Global pharmacovigilance departments may exist in a limited 
number of regional hubs, with each hub having a senior 
pharmacovigilance member who provides oversight 
ROLES AND RESPONSIBILITIES OF THE 
PHARMACOVIGILANCE TEAM 
• In different regions of the world, job titles vary for similar roles on the 
pharmacovigilance 
• team. The titles drug, or product, safety associate or safety specialist may 
be used interchangeably with pharmacovigilance associate; the title drug 
safety physician is commonly used when referring to the physicians 
providing pharmacovigilance. 
• Head of Pharmacovigilance 
• The head of pharmacovigilance plays a critical role in the 
pharmacovigilance department, and is the person ultimately responsible 
for all of the safety and risk management activities performed within the 
department.  
• Typically, he or she will have many years of experience in 
pharmacovigilance and be an authority on pharmacovigilance regulations 
and reporting requirements. In addition to providing leadership and 
oversight within the department, the head of pharmacovigilance acts as a 
senior resource throughout the company on matters such as safety 
strategy, regulatory and safety risk management, safety compliance, and 
safety quality assurance. 
ROLES AND RESPONSIBILITIES OF THE 
PHARMACOVIGILANCE TEAM 
Drug Safety Physician/Directors of Drug Safety 
• It is frequently necessary for the medical monitor to remain blinded as to 
the medicinal product causing an adverse reaction in a clinical trial. 
Knowledge of the treatment arm may bias the medical monitor in 
decisions affecting other aspects of the study.  
• In such cases, a physician not otherwise associated with the study will be 
assigned to assess adverse events, possibly as an unblinded medical 
reviewer. In large, global pharmaceutical companies, these DSPs exist in 
the pharmacovigilance department completely separate from the medical 
monitors on the clinical team.  
• In smaller companies where physicians may play multiple roles, it is 
important to firewall blinded and unblinded medical staff in order to 
protect the integrity of the clinical data. 
• Other responsibilities of the DSPs include medical review of aggregate 
data and reports. More experienced DSPs or directors of drug safety are 
involved in signal detection and analysis. 
• Some may be responsible for creating and implementing development 
risk minimization plans (Europe) or risk evaluation and mitigation plans 
(USA), which are now required by many regulatory authorities. 
ROLES AND RESPONSIBILITIES OF THE 
PHARMACOVIGILANCE TEAM 
Qualified Person for Pharmacovigilance in Europe 
The QPPV is a required role for all pharmaceutical companies in 
Europe, but not yet required in other regions of the world. A named 
person is responsible for all aspects of pharmacovigilance for a 
medicinal product.  
The QPPV must be a physician or someone acting under the 
supervision of a qualified physician. He or she ensures the adequacy of 
the pharmacovigilance system and full compliance with meeting 
regulatory obligations and timelines for safety 
reporting.  
Therefore, the QPPV must be very experienced in clinical trial safety as 
well as safety regulations, compliance, and policy.  
The QPPV oversees the pharmacovigilance plan development and 
proactive risk minimization strategies. He or she is the single point of 
contact for safety with the regulatory authorities. 
ROLES AND RESPONSIBILITIES OF THE 
PHARMACOVIGILANCE TEAM 
• Pharmacovigilance/Drug Safety Product Manager 
• The pharmacovigilance or drug safety product manager 
(DSPM) is an experienced member of the pharmacovigilance 
department assigned to oversee specific safety products, 
usually when large numbers of safety staff are required. 
Examples of projects requiring a DSPM include studies with 
large numbers of SAEs, case reports, studies with clinical 
endpoints that are also SAEs, projects involving a number of 
different safety functions (e.g. case reporting and regulatory 
submission, literature review, and aggregate reporting), and 
other safety projects of special interest 
ROLES AND RESPONSIBILITIES OF THE 
PHARMACOVIGILANCE TEAM 
Drug Safety Associate 
• The role of a DSA is to monitor and track SAEs, serious and non-serious ADRs, 
and other medically related product information. It is paramount to ensure the 
timely processing and reporting of such information in accordance with company 
and regulatory reporting timelines. 
• The DSA usually has an educational background in one of the life sciences; it is 
also advantageous to have a working knowledge of medical terminology.  
• Many DSAs are pharmacists, or other allied health professionals. The DSA works 
under the supervision of the DSPM, director of drug safety, QPPV, or medical 
monitor. 
• Some of the other functions performed by the DSA include, but are not limited to, 
developing safety plans, providing input to and reviewing study safety tracking 
reports for accuracy and quality; maintaining electronic and paper files; assisting 
the medical monitor with the documentation and processing of routine exceptions 
and rescreen approvals; 
• performing safety review of clinical [case report forms (CRFs)] and patient 
laboratory data; 
• liaising with sponsors, investigational sites, and/or reporters regarding safety 
issues;  
• participating in project team meetings and teleconferences. 
ROLES AND RESPONSIBILITIES OF THE 
PHARMACOVIGILANCE TEAM 
Medical Assistant 
The medical assistant plays an important role in maintaining efficient 
and accurate organization of documents and information within the 
department by providing administrative support to the 
pharmacovigilance team. 
 Duties of the medical assistant include filing; faxing; assisting with the 
planning and organization of meetings, teleconferences, and training 
sessions; maintaining meeting minutes; handling mailing activities; 
documenting contacts and submitting to appropriate personnel; 
maintaining office supplies and equipment; creating, maintaining and 
auditing work tracking systems; and ensuring accuracy and audit 
readiness of the departmental files and file room. In some cases, 
medical assistants may be trained as data entry personnel and can assist 
in the data entry of safety information into appropriate safety databases. 
ROLES AND RESPONSIBILITIES OF THE 
PHARMACOVIGILANCE TEAM 
Safety Systems Specialists 
Owing to the large amounts of data involved, numerous 
databases and technology systems are required to manage the 
daily workflow associated with pharmacovigilance, including 
individual case management and aggregate data analysis.  
This requires staff who have backgrounds in information 
technology (IT). In some cases, these staff are further specialized 
in the creation, validation, and maintenance specifically of safety 
systems.  
In smaller companies, the safety systems specialist may be part 
of the IT department, assigned as needed to support 
pharmacovigilance. 
ROLES AND RESPONSIBILITIES OF THE 
PHARMACOVIGILANCE TEAM 
Pharmacovigilance Trainer 
In the current dynamic environment surrounding pharmacovigilance 
and risk management, ongoing training for pharmacovigilance staff is 
essential to maintain awareness of current global and local regulations, 
policies, and guidelines.  
Pharmacovigilance training includes subject matter training on the 
therapeutic area of the product under development and specific training 
on the science related to the investigational product. Often the medical 
monitor or an expert in another therapeutic area supplies this training. 
Training related specifically to pharmacovigilance is continuous, with 
more senior staff reviewing and mentoring the junior staff.  
Beyond a certain size, however, staff specifically dedicated to 
performing pharmacovigilance training is usually necessary. All 
training should be documented and filed appropriately. 
Steps in Serious Adverse Event Case Processing 
1. When an investigator, healthcare provider, or clinical site monitor identifies a potential 
SAE, the event is reported to the sponsor immediately. 
2. Upon receipt of an SAE at the pharmacovigilance department, the report is assessed as 
to 
whether it fulfills the minimum requirements for reporting. 
3. A valid case is checked for duplication, i.e. whether the same case was previously 
reported, 
or whether this is follow-up information on a previously opened case. 
4. If the case is identified as valid for initial data entry, it will undergo a triage step, being 
reviewed for expectedness, relatedness, and seriousness, with special attention as to 
whether the case is fatal or life threatening. This determines the appropriate timeline for 
processing and reporting to the regulatory authorities. 
5. The case then undergoes data entry, a case narrative is created and the case undergoes 
medical review. Any missing or unclear information is queried and added to the case. 
6. Once all of these activities are completed and quality checked, the case is finalized 
within the allotted timeframe and if expedited reporting is required the information is 
sent to the 
appropriate recipients. 
7. The process is repeated as additional information becomes available until the event is 
resolved or no further information can be obtained. 
• Pharmacovigilance and risk management are an essential part of 
pharmaceutical product development and commercialization, the 
activities of which are highly regulated in many parts of the world. 
Rare adverse events may not be identified until large numbers of 
patients receive the product, so pharmacovigilance and risk 
management must extend throughout the product’s life cycle.  
• Benefit and risk must be continually assessed as more is learned 
about the product through its use. Building pharmacovigilance and 
risk management capacity requires a systematic approach to ensure 
that all safety aspects are monitored and addressed properly. 
• Since capacity building takes time and resources, outsourcing of 
certain activities may enable capacity building to proceed before all 
capabilities can be done in-house.  
• The use of a limited number of safety centers is a viable and cost-
effective option, provided there are good processes, good tools, and 
good communication of responsibilities and events. 
